Samir Undevia, MD
Hematology-Oncology · Chicago, ILNPI 1740228857
Payments from drug & device makers
What this record shows
This record is dominated by travel and lodging: $1,075 of the $1,703 with a category attached, or 63.1%. Astrazeneca UK Limited accounts for 72.8% of it on its own, with 14 other manufacturers making up the rest. Reporting peaked in 2019 at $1,312 and has fallen 91.6% since, to $110 in 2025.
Across 31 payments — averaging $54.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Astrazeneca UK Limited$1K
- Tempus AI, Inc$106
- Pfizer$64
- Novartis$63
- E.r. Squibb & Sons, L.L.C.$35
- Amgen$24
- plus $172 from 9 others
Across 9 payments — averaging $118.99 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- GSK$1K
What the payments were for
- Travel & lodging$1,07563%
- Food & beverage$62837%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Astrazeneca UK Limited | 8 | $1,239 |
| Tempus AI, Inc | 5 | $106 |
| Pfizer | 3 | $64 |
| Novartis | 3 | $63 |
| E.r. Squibb & Sons, L.L.C. | 2 | $35 |
| Amgen | 1 | $24 |
| Array Biopharma Inc | 1 | $24 |
| Cardinal Health 414 LLC | 1 | $24 |
| Bristol Myers Squibb | 1 | $22 |
| Merck | 1 | $19 |
| Seagen Inc. | 1 | $18 |
| Pharmacyclics LLC, An Abbvie Company | 1 | $17 |
| Boehringer Ingelheim | 1 | $17 |
| Sanofi | 1 | $16 |
| Genentech USA, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- IMFINZI$1,049
How this compares
Too few hematology-oncology providers in Illinoisto place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LynparzaOlaparib | 22 | $425,875 |
| KisqaliRibociclib Succinate | 24 | $419,959 |
| OgsiveoNirogacestat Hydrobromide | 12 | $343,535 |
| EliquisApixaban | 146 | $134,051 |
| Imatinib Mesylate | 13 | $90,024 |
| XareltoRivaroxaban | 85 | $77,118 |
| Abiraterone Acetate | 20 | $19,783 |
| Anastrozole | 201 | $3,710 |
| Tamoxifen Citrate | 46 | $1,145 |
| Letrozole | 34 | $829 |
| Hydroxyurea | 22 | $523 |
| Levothyroxine Sodium | 51 | $515 |
| Potassium Chloride | 54 | $466 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 26 | $405 |
| Acyclovir | 20 | $390 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| NovartisKisqali | $63 | $419,95924 claims |
| PfizerEliquis | $64 | $134,051146 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few hematology-oncology providers in Illinoison file to place this against a meaningful peer group, so we don't.
Other hematology-oncology in Chicago
- Joanna StankiewiczChicago$2K
- Ann MauerChicago$1K
- Shawn KothariChicago$0
- Brandon BungoChicago$0
- Jane ChurpekChicago$0
- Michael HawkingChicago$0
- Megan RandallChicago$0
- John ShowelChicago$0
- Tabraiz MohammedChicago$0
- Sujatha RaoCarbondale$933
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.